epothilone F: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 9914741 |
CHEMBL ID | 513726 |
SCHEMBL ID | 4293 |
MeSH ID | M0388124 |
Synonym |
---|
CHEMBL513726 |
epothilone f |
SCHEMBL4293 |
UKIMCRYGLFQEOE-RGJAOAFDSA-N |
AC-28331 |
208518-52-9 |
EX-A5465 |
(1s,3s,7s,10r,11s,12s,16r)-7,11-dihydroxy-3-((e)-1-(2-(hydroxymethyl)thiazol-4-yl)prop-1-en-2-yl)-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione |
(1s,3s,7s,10r,11s,12s,16r)-7,11-dihydroxy-3-[(e)-1-[2-(hydroxymethyl)-1,3-thiazol-4-yl]prop-1-en-2-yl]-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione |
4,17-dioxabicyclo(14.1.0)heptadecane-5,9-dione, 7,11-dihydroxy-3-((1e)-2-(2-(hydroxymethyl)-4-thiazolyl)-1-methylethenyl)-8,8,10,12,16-pentamethyl-, (1s,3s,7s,10r,11s,12s,16r)- |
unii-gfx93bx7k3 |
gfx93bx7k3 , |
(1s,3s,7s,10r,11s,12s,16r)-7,11-dihydroxy-3-((1e)-2-(2-(hydroxymethyl)-4-thiazolyl)-1-methylethenyl)-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo(14.1.0)heptadecane-5,9-dione |
(-)-epothilone f |
CS-0092694 |
AKOS040751704 |
HY-127079 |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID356712 | Cytotoxicity against mouse L929 cells | 2001 | Journal of natural products, Jul, Volume: 64, Issue:7 | New natural epothilones from Sorangium cellulosum, strains So ce90/B2 and So ce90/D13: isolation, structure elucidation, and SAR studies. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |